Sakditad Saowapa, Hematology-Oncology Fellow at the University of Iowa, shared a post on LinkedIn:
“FDA Accelerated Approval (2 Jul 2025)
Sunvozertinib (Zegfrovy) approved for metastatic NSCLC with EGFR exon 20 insertion after platinum chemotherapy.
- WU-KONG1B trial (n=85)
- ORR: 46% (95% CI: 35–57%)
- DoR: 11.1 months (95% CI: 8.2–NE)
- Companion Diagnosis: Oncomine Diagnosis Express Test
- Warnings: ILD/pneumonitis, GI, skin, ocular, embryo-toxic.”
More posts featuring Sakditad Saowapa.